MTS Health Partners

Zymeworks Inc. is a clinical-stage biopharmaceutical company based in Vancouver, Canada, that specializes in the discovery, development, and commercialization of biotherapeutics, primarily for cancer treatment. The company’s leading candidates include ZW25, a bispecific antibody currently undergoing Phase I and II clinical trials targeting various cancers, and ZW49, a bispecific antibody-drug conjugate in Phase I trials for advanced HER2-expressing cancers. Zymeworks employs advanced computational biotechnology techniques, utilizing proprietary molecular modeling and high-performance computing to optimize therapeutic antibodies and other protein-based therapeutics. The company has established strategic partnerships and collaborations with several major pharmaceutical firms, including Merck, Eli Lilly, and Bristol-Myers Squibb, among others, to enhance its research and development efforts. Founded in 2003, Zymeworks continues to focus on developing innovative solutions for cancer and other serious diseases.

Celerion, Inc. specializes in clinical research and applied translational medicine services for pharmaceutical and biotechnology companies both domestically and internationally. Established in 2010, the company operates from its headquarters in Lincoln, Nebraska, with additional facilities in Tempe, Arizona, and West Conshohocken, Pennsylvania. Celerion's offerings encompass a broad range of services, including global clinical research, data management, biometrics, bioanalytical services, and drug development support. The company is particularly focused on generating critical data early in the drug development process, utilizing innovative strategies to facilitate informed decision-making regarding early drug development and clinical pharmacology. With a robust clinical capacity and experienced scientific staff, Celerion aims to expedite the

myNEXUS, Inc. is a healthcare management company that specializes in technology-driven care management services, focusing on enabling individuals to manage their health effectively at home. The company provides daily remote monitoring of patients' health, particularly targeting those with chronic conditions such as congestive heart failure, diabetes, and hypertension. Through its myLINK2Care system, myNEXUS ensures immediate responses to health issues, thereby reducing the likelihood of unnecessary healthcare visits and costly hospitalizations. The company also offers benefits management services that utilize medical data to decrease the risk of 30-day readmissions. myNEXUS serves a diverse clientele, including insurers, employers, and family members, addressing the healthcare needs of individuals across the United States. Founded in 2014, the company is headquartered in Brentwood, Tennessee.